U.S. markets closed

ResMed Inc. (RMD)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
241.80+3.10 (+1.30%)
At close: 04:00PM EDT
246.15 +4.35 (+1.80%)
After hours: 05:21PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close238.70
Bid180.00 x 1000
Ask246.15 x 800
Day's Range235.58 - 241.97
52 Week Range189.40 - 301.34
Avg. Volume578,701
Market Cap35.372B
Beta (5Y Monthly)0.47
PE Ratio (TTM)45.62
EPS (TTM)5.30
Earnings DateAug 11, 2022
Forward Dividend & Yield1.68 (0.69%)
Ex-Dividend DateMay 11, 2022
1y Target Est244.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-13% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for RMD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ResMed Inc.
    Analyst Report: ResMed Inc.ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
    Fair Value
    Economic Moat
    17 days agoMorningstar
View more
  • Zacks

    NuVasive (NUVA) Lags Q2 Earnings Estimates

    NuVasive (NUVA) delivered earnings and revenue surprises of -14.55% and 1.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    ResMed Acquires Leipzig-based mementor with Insomnia Digital Health Solution somnio

    Acquisition lays foundation to build ResMed’s digital sleep medicine portfolio in Germanysomnio digital health application focused on improving sleep in patients with diagnosed insomnia, filling care gap and providing alternative to prevailing drug therapy mementor to be integrated into ResMed in Germany as a separate business segment and will serve as a platform for further developments in the field of digital health MARTINSRIED, Germany and LEIPZIG, Germany, Aug. 02, 2022 (GLOBE NEWSWIRE) -- R

  • Benzinga

    Semiconductor Shortages - See How ResMed Is Tackling

    ResMed Inc (NYSE: RMD) has redesigned the AirSense 10 to eliminate a short-supply semiconductor chipset used for cellular communications chips. Instead of offering wireless communications capability, the new AirSense 10 "Card to Cloud" models collect the patient's data on an SD card, which can then be mailed to the provider and uploaded to the cloud. Needham notes that ResMed continues to sell its AirSense 10 and AirSense 11 models with cellular connectivity. The AirSense 10 Card to Cloud is now